An open‐label, first‐in‐human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myeloma.
Saved in:
| Title: | An open‐label, first‐in‐human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myeloma. |
|---|---|
| Authors: | Kapoor, Prashant1 (AUTHOR), Nathwani, Nitya2 (AUTHOR), Jelinek, Tomas3 (AUTHOR), Pour, Ludek4 (AUTHOR), Perrot, Aurore5 (AUTHOR), Dimopoulos, Meletios‐Athanasios6 (AUTHOR), Huang, Shang‐Yi7 (AUTHOR), Spicka, Ivan8 (AUTHOR), Chhabra, Saurabh9 (AUTHOR), Lichtman, Eben10,11 (AUTHOR), Mateos, Maria‐Victoria12 (AUTHOR), Kanagavel, Dheepak13 (AUTHOR), Zhao, Liang14 (AUTHOR), Guillemin‐Paveau, Helene13 (AUTHOR), Macé, Sandrine13 (AUTHOR), van de Velde, Helgi15 (AUTHOR), Richardson, Paul G.16 (AUTHOR) paul_richardson@dfci.harvard.edu |
| Source: | European Journal of Haematology. Nov2024, Vol. 113 Issue 5, p593-605. 13p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 09024441 |
|---|---|
| DOI: | 10.1111/ejh.14270 |
